Psoriasis News and Research

Latest Psoriasis News and Research

AARDA creates new multi-media public service campaign for AD patients

In response to a recent study that found roughly one-third of prescriptions for autoimmune disease patients go unfilled and a high level of physician mistrust exists among AD patients, the American Autoimmune Related Diseases Association, Inc. has created a new multi-media public service campaign with tools designed to help patients make informed decisions about newly-prescribed therapies and treatments.

17 Apr 2013

FDA approves Taro's NDA for Topicort Topical Spray

Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its New Drug Application Topicort (desoximetasone) Topical Spray, 0.25%.

15 Apr 2013

Data on PV-10 combination therapy presented at AACR Annual Meeting

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented data on PV-10 combination therapy today at the American Association for Cancer Research Annual Meeting in Washington, DC.

11 Apr 2013

Patients with psoriasis carry increased risk of developing severe co-morbid conditions

The International Federation of Psoriasis Associations, IFPA, commends the World Health Organization for raising awareness of the risks associated with high blood pressure and calls for healthcare professionals to regularly scan for the condition in patients with psoriasis.

9 Apr 2013

Anacor signs research agreement to discover drug candidates to treat neglected diseases

Anacor Pharmaceuticals today announced that it has signed a research agreement with the Bill & Melinda Gates Foundation (the Gates Foundation) to discover drug candidates intended to treat two filarial worm diseases (onchocerciasis, or river blindness, and lymphatic filariasis, commonly known as elephantiasis) and tuberculosis.

9 Apr 2013

Arena Pharmaceuticals kicks off APD334 Phase 1 clinical trial for treatment of autoimmune diseases

Arena Pharmaceuticals, Inc. announced today the initiation of dosing in a Phase 1 clinical trial of APD334, a novel oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of autoimmune diseases.

6 Apr 2013

Fruit fly study offers clues to wound healing

A person's skin and a fruit fly's exoskeleton, called a "cuticle" may not look alike, but both coverings protect against injury, infection, and dehydration.

6 Apr 2013

USPTO issues Notice of Allowance on Antares Pharma's patent application for VIBEX QS device

Antares Pharma, Inc. announced that it has received a Notice of Allowance from the U.S. Patent Trade Office on a patent application for the VIBEX QuickShot device, the latest advancement in its proprietary line of VIBEX auto-injector systems.

5 Apr 2013

Dermatology researcher secures federal grant to explore psoriasis

A dermatology researcher at Case Western Reserve University School of Medicine has secured a five-year, $1.9 million federal grant to explore whether a specific molecule may play a pivotal role in the development and progression of psoriasis.

5 Apr 2013

Same factor that helps fight off severe inflammatory ailments also functions as enemy

The same factor in our immune system that is instrumental in enabling us to fight off severe and dangerous inflammatory ailments is also a player in doing the opposite at a later stage, causing the suppression of our immune response.

4 Apr 2013

arGEN-X advances ARGX-112 into formal preclinical development

arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed ARGX-112, its fourth therapeutic candidate, into formal preclinical development.

25 Mar 2013

Researchers develop promising drug candidate to treat psoriasis

Ben-Gurion University of the Negev researchers, in collaboration with Teva Pharmaceutical Industries Ltd., have developed a promising drug candidate to treat psoriasis.

21 Mar 2013

Drugs that combat ageing may be available within five years

Drugs that combat ageing may be available within five years, following landmark work led by an Australian researcher.

11 Mar 2013

RA patients who initiate anti-TNF therapies do not have higher risk of shingles: Study

Although patients with rheumatoid arthritis have a disproportionately higher incidence of herpes zoster (shingles), an analysis that included nearly 60,000 patients with RA and other inflammatory diseases found that those who initiated anti-tumor necrosis factor therapies were not at higher risk of herpes zoster compared with patients who initiated nonbiologic treatment regimens, according to a study appearing in the March 6 issue of JAMA.

7 Mar 2013

Study reveals increased dietary salt intake may lead to autoimmune disorders

Increased dietary salt intake can induce a group of aggressive immune cells that are involved in triggering and sustaining autoimmune diseases.

7 Mar 2013

Insight into how Th17 cell growth influences development of immune responses

New work from the Broad Institute's Klarman Cell Observatory, Brigham and Women's Hospital, Harvard University, MIT, and Yale University expands the understanding of how one type of immune cell - known as a T helper 17 or Th17 cell - develops, and how its growth influences the development of immune responses.

7 Mar 2013

Call for universal CAH screening

An analysis of 100 years of epidemiological data from Sweden has shown that neonatal screening for congenital adrenal hyperplasia is as effective at improving survival in boys as it is in girls.

5 Mar 2013

Anti-metabolic syndrome efforts needed for young ALL survivors

Children with acute lymphoblastic leukemia are at risk for developing the metabolic syndrome during maintenance therapy, suggest study findings.

5 Mar 2013

Biogen announces FDA acceptance of rFIXFc BLA for treatment of hemophilia B

Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) for the marketing approval of recombinant factor IX Fc fusion protein (rFIXFc) for the treatment of hemophilia B and granted the company a standard review timeline.

5 Mar 2013

Idera announces new data from IMO-3100 and IMO-8400 preclinical study on psoriasis

Idera Pharmaceuticals, Inc. today announced the presentation of new data showing that its selective Toll-like receptor antagonists, IMO-3100 and IMO-8400, normalized the gene expression of important cytokines in a preclinical study of skin inflammation that is commonly used as a model of psoriasis.

4 Mar 2013